APSR2026-660

 
Late-Breaking
Submitted
Poster Presentation
 
AP02-017
P25
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1220989-46904-poster for APSR_432223.pdf
Format: PDF Only
05. Respiratory Infections (non-tuberculous)
3

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Wenwen Wang * Zhongshan Hospital, Fudan University Department of Respiratory and Critical Care Medicine Shanghai China
Yuanlin Song - Zhongshan Hospital, Fudan University Department of Respiratory and Critical Care Medicine Shanghai China
Jinfu Xu - Tongji Hospital, Tongji University Department of Respiratory and Critical Care Medicine Shanghai China
 
 
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Wenwen
Wang
wang.wenwen@zs-hospital.sh.cn
+8618817871089
31-40
China
Original Research
A Mismatch Between Physiology and Treatment in Bronchiectasis with Airflow Obstruction—Data from BE-China
Maximum 25 words
Abstract Content
Airflow obstruction is common in bronchiectasis, yet its clinical implications and management remain unclear. We evaluated its prevalence, determinants, and treatment patterns using BE-China registry data.
This cross-sectional study included 10,324 patients, of whom 4,840 with spirometry were analyzed. Airflow obstruction was defined by spirometry. Characteristics and treatment patterns were compared between groups. Multivariable logistic regression identified factors associated with airflow obstruction, inhaler use, and inhaled corticosteroid (ICS) use. Results are reported as odds ratios (ORs) with 95% confidence intervals (CIs). Sensitivity analyses were performed.
Airflow obstruction was present in 2,070 of 4,840 patients (42.8%). Patients with airflow obstruction had more severe disease, including greater radiological severity, higher symptom burden, and worse health-related quality of life (all P<0.001). Despite its high prevalence, inhaler use was low and poorly aligned with physiological status. Only 446 of 4,768 patients (9.4%) received inhalers, including 132 (29.6%) without airflow obstruction, most of whom had PRISm or significant symptoms. Conversely, only 15.4% of patients with airflow obstruction received inhalers. In multivariable analysis, inhaler use was associated with airflow obstruction (OR 3.47), PRISm (OR 2.03), symptoms (OR 1.47), prior hospitalization (OR 1.53), COPD (OR 2.43), and asthma (OR 3.12). ICS use was uncommon (5.1%). After excluding COPD and asthma, eosinophils ≥300 cells/μL were associated with ICS use (OR 2.68), along with airflow obstruction (OR 3.50) and symptoms (OR 1.97), whereas PRISm and radiological severity were not. Airflow obstruction was associated with smoking (OR 1.63), age (OR 1.01), Reiff score (OR 1.10), and Pseudomonas aeruginosa isolation (OR 2.02).
Airflow obstruction is highly prevalent in bronchiectasis and is associated with greater disease severity, chronic infection, and symptom burden. However, a mismatch exists between physiological impairment and treatment allocation in real-world practice. Inhaler use reflects a hierarchical process involving airflow limitation, PRISm, and symptoms, whereas ICS use is more closely associated with eosinophilic inflammation and remains linked to eosinophilia beyond COPD and asthma. These findings support more phenotype-driven management strategies in bronchiectasis.
 
 
 
 
 
No
Yes
https://storage.unitedwebnetwork.com/files/1285/1220989-37089-table1_381160.jpg
JPG or JPEG or PNG format ONLY
bronchiectasis, airflow obstruction, inhaler use
maximum 3 keywords and no abbreviations, separated by commas
The authors declare there are no conflicts of interests.
349